Lamivudine

Generic Name: Lamivudine

Brand Names: Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁N_₃O_₃S

CAS Number: 134678-17-4

Unique Ingredient Identifier: 2T8Q726O95

Background: A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication: For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions: Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Phase 2

Terminated

Conditions: HIV Infections

Interventions: Drug: Raltegravir (MK-0518)
Drug: Tenofovir
Drug: Nevirapine
Drug: Emtricitabine
Drug: Lamivudine
Drug: Lopinavir
Drug: Ritonavir
Drug: Atazanavir
Drug: Darunavir

First Posted Date: 2014-04-17

Last Posted Date: 2019-04-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 11

Registration Number: NCT02116660

Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery

Phase 3

Conditions: Hepatocellular Carcinoma
Recurrence

Interventions: Drug: Lamivudine
Drug: Aspirin

First Posted Date: 2013-09-06

Last Posted Date: 2019-08-05

Lead Sponsor: Fudan University

Target Recruit Count: 112

Registration Number: NCT01936233

Locations: 🇨🇳
Liver Cancer Institute, Shanghai, Shanghai, China

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Phase 2

Conditions: Non-Hodgkin Lymphoma
Hepatitis B Reactivation

Interventions: Drug: Entecavir
Drug: Lamivudine

First Posted Date: 2013-08-02

Last Posted Date: 2013-08-02

Lead Sponsor: Fudan University

Target Recruit Count: 82

Registration Number: NCT01914744

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation

Phase 3

Conditions: Chronic HBV With Severe Exacerbation

Interventions: Drug: lamivudine
Drug: Tenofovir

First Posted Date: 2013-05-07

Last Posted Date: 2014-09-16

Lead Sponsor: Kaohsiung Veterans General Hospital.

Target Recruit Count: 120

Registration Number: NCT01848743

Locations: 🇨🇳
Kaohsiung Veterans General Hospigal, Kaohsiung, Taiwan
🇨🇳
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus

Phase 4

Completed

Conditions: Hepatitis B Infection
Chronic Infection
Viremia

Interventions: Drug: Lamivudine
Drug: Telbivudine

First Posted Date: 2013-02-11

Last Posted Date: 2013-07-30

Lead Sponsor: Hua Zhang

Target Recruit Count: 700

Registration Number: NCT01788371

Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

Phase 4

Completed

Conditions: Chronic Hepatitis B
Late Pregnancy
Transmission
Complication

Interventions: Drug: Telbivudine
Drug: Lamivudine

First Posted Date: 2012-12-06

Last Posted Date: 2013-07-30

Lead Sponsor: Beijing YouAn Hospital

Target Recruit Count: 700

Registration Number: NCT01743079

Locations: 🇨🇳
Beijing YouAn Hospital, Beijing, Beijing, China

A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: FZD
Drug: 3TC
Drug: EFV
Drug: AZT

First Posted Date: 2012-10-26

Last Posted Date: 2018-03-07

Lead Sponsor: Michael Hoelscher

Target Recruit Count: 120

Registration Number: NCT01714414

Locations: 🇨🇮
Service des Maladies Infectieuses et Tropicales, CHU de Treichville,, Abidjan, Côte D'Ivoire
🇹🇿
NIMR - Mbeya Medical Research Programme,, Mbeya, Tanzania

Abacavir and Lamivudine PK in Children

Phase 2

Completed

Conditions: HIV

Interventions: Drug: abacavir
Drug: 3TC

First Posted Date: 2012-08-02

Last Posted Date: 2016-02-22

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 30

Registration Number: NCT01656122

Locations: 🇹🇭
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand

Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation

Phase 4

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: Lamivudine
Drug: Entecavir

First Posted Date: 2012-06-25

Last Posted Date: 2016-10-18

Lead Sponsor: Taichung Veterans General Hospital

Target Recruit Count: 17

Registration Number: NCT01627223

Locations: 🇨🇳
ChengChing Hospital, Taichung, Taiwan
🇨🇳
Chung Shan Medical University Hospital, Taichung, Taiwan
🇨🇳
National Taiwan University Hospital Yu-Lin Branch, YuLin, Taiwan

and more 5 locations

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Phase 3

Terminated

Conditions: HIV

Interventions: Drug: Atazanavir
Drug: Ritonavir
Drug: Tenofovir/Emtricitabine
Drug: Lamivudine

First Posted Date: 2012-06-15

Last Posted Date: 2024-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3

Registration Number: NCT01620944

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy